Contrave Advisory Committee Date May Give Orexigen Late-Mover Advantage
This article was originally published in The Pink Sheet Daily
Executive Summary
Earlier panel critiques of Contrave rivals should provide insight on how FDA is weighing risk versus benefit in obesity space.